FreeStyle Libre Monitoring in T2DM

Inclusion Criteria:

• Males and females living with type 2 diabetes mellitus (T2DM) who are aged ≥ 18 and ≤ 75 years

• On one or more non-insulin glucose lowering agent(s)

• HbA1c ≥ 69 mmol/mol

• Able to provide written informed consent

Exclusion Criteria:

• Participants with a life expectancy of less than 1 year

• Participants with cognitive dysfunction or neurological disorder, which willinterfere with regular, flash glucose monitoring

• Participants with chronic kidney disease (CKD) with eGFR < 45ml/min/1.73m2 ordecompensated liver disease or decompensated congestive cardiac failure

• Myocardial infarction in the preceding 3 months or if percutaneous coronaryintervention planned in the next 6 months

• Participants on supra-physiological doses of steroids, for example, Prednisolone forthe treatment of Rheumatoid arthritis

• Participants on active dialysis or planned for dialysis treatment during the study

• Currently participating in another device or drug study that could affect glucosemeasurements or management

• Women who are pregnant, breastfeeding or planning to become pregnant. Women shoulduse a reliable form of contraception throughout the study

• Participants who are already using continuous glucose monitoring (CGM)

• Participants who have pacemakers, implanted cardioverter defibrillator devices orneurostimulators

• Participants with an allergy to medical grade adhesive

• A blood transfusion in the preceding 3 months or a planned blood transfusion duringthe course of the study